<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185402</url>
  </required_header>
  <id_info>
    <org_study_id>19-28923</org_study_id>
    <nct_id>NCT04185402</nct_id>
  </id_info>
  <brief_title>Azithromycin Reduction to Reach Elimination of Trachoma</brief_title>
  <acronym>ARRET</acronym>
  <official_title>Azithromycin Reduction to Reach Elimination of Trachoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Programme National de Santé Oculaire (PNSO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a randomized controlled trial of discontinuation versus
      continuation of annual mass azithromycin distribution in hypoendemic communities of Maradi,
      Niger. The investigators will randomize communities with up to 20% Trachomatous Inflammation
      - Follicular (TF) prevalence following at least 5 years of mass azithromycin distribution to
      discontinuation or continuation of 3 additional years of annual mass azithromycin
      distribution.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular chlamydia measured in a population-based sample of 0-9 year-old children</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed by PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infectious load of chlamydia among 0-9 year-old children infected with ocular chlamydia</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival inflammation</measure>
    <time_frame>36 months</time_frame>
    <description>Assessed from conjunctival photography. Clinical photographs of the conjunctiva will be assessed by masked graders according to the grading scale described by the WHO Simplified Grading System.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Trachoma</condition>
  <arm_group>
    <arm_group_label>Azithromycin Continuation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin Discontinuation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.</description>
    <arm_group_label>Azithromycin Continuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of appropriate informed consent

          -  Stated willingness to comply with all study procedures

          -  Live in one of the 80 communities with up to 20% prevalence of TF selected for the
             trial

        Exclusion Criteria:

          -  Does not consent to participation

          -  Unwilling to comply with all study procedures

          -  Does not live in one of the 80 communities with up to 20% prevalence of TF selected
             for the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Oldenburg, ScD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ariana Austin, MS</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Oldenburg, ScD, MPH</last_name>
    <phone>(415) 502-8843</phone>
    <email>catherine.oldenburg@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariana Austin, MS</last_name>
    <phone>(415) 502-0275</phone>
    <email>ariana.austin@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Programme National de Santé Oculaire (PNSO)</name>
      <address>
        <city>Niamey</city>
        <country>Niger</country>
      </address>
    </facility>
    <contact>
      <last_name>Abdou Amza, MD</last_name>
      <phone>+227 96967009</phone>
      <email>dr.amzaabdou@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Abdou Amza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Niger</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trachoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

